Am Fam Physician. 2009 Sep 1;80(5):455-456.
Should varicella vaccine be given as postexposure prophylaxis for prevention in healthy unvaccinated children and adults?
Varicella vaccine appears to be effective in preventing or modifying the severity of the disease in healthy unvaccinated children if administered within three days of exposure. Data are insufficient to support or refute the use of the vaccine as postexposure prophylaxis in adults and adolescents.
The probability is greater than 90 percent that varicella infection will occur in a susceptible person following exposure.1 Secondary bacterial infection of soft tissues is the most common complication, but more serious illnesses have been reported, including pneumonia, dehydration, hepatitis, ataxia, and encephalitis.2
In this Cochrane review, the authors could not perform a meta-analysis because the included studies varied greatly in methodology and measured outcomes. However, the authors found three randomized and quasirandomized controlled trials of postexposure prophylaxis with varicella vaccine in children. In these studies, 13 of 56 vaccine recipients developed varicella, compared with 42 of 54 recipients of placebo or no vaccine (18 versus 78 percent; number needed to treat = 2). Twelve of the 13 recipients who developed chicken pox had mild disease with fewer than 50 lesions. Most participants (i.e., 70 percent) received the vaccine within three days of exposure. Therefore, it is not possible to assess the effectiveness of the vaccine in preventing or modifying the disease if given after three days of exposure because of the small number of participants who received the vaccine on days 4 or 5. There are no data regarding the potential benefit of administering a second dose to one-dose vaccine recipients after exposure. However, the Advisory Committee on Immunization Practices (ACIP) recommends giving a second dose to patients who have previously received one dose of vaccine.3
The safety of varicella vaccine when used as post-exposure prophylaxis was not adequately assessed in these three studies. Postlicensure studies of vaccine effectiveness have indicated that varicella vaccine has a good safety profile.4,5 The most common adverse events are rash within 42 days of vaccination, fever, and injection-site reactions.3
This review does not find sufficient data to support or refute the use of varicella vaccine as postexposure prophylaxis in adolescents and adults. Nevertheless, according to ACIP, postexposure vaccination should be offered to adults without evidence of immunity. ACIP also recommends postexposure prophylaxis for all exposed household contacts.3
Macartney K, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database Syst Rev. 2008;(3):CD001833.
REFERENCESshow all references
1. Simpson RE. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet. 1952;2(6734):549–554....
2. Gershon AA, Takahashi M, Seward J. Varicella vaccine. In: Plotkin SA, Offit PA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia, Pa.: Saunders; 2004:783–824.
3. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1–40.
4. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine [published correction appears in JAMA. 2000;284(24):3129]. JAMA. 2000;284(10):1271–1279.
5. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2000;19(7–8):916–923.
Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions